Clinical Trial Update: A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects [Phase 1]

View source ↗

Summary

A Phase 1 single-dose PK and safety study of GSK2838232 in healthy subjects, with and without ritonavir, was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• GSK2838232
• Ritonavir (Ritonavir)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infection, Human Immunodeficiency Virus | Phase 1 | Status: TERMINATED